MedPath

Double Blind Study of TCV-116 in Patients with Hypertensio

Phase 3
Conditions
Essential Hypertension
Registration Number
JPRN-jRCT2080221017
Lead Sponsor
Takeda Pharmaceutical Company Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Mild to moderate essential hypertension

Exclusion Criteria

1.History or symptom of sever cardiovascular complication(hear failure,stroke)
2.Hypertension caused by other disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diastolic blood pressure
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath